Is Graviola Fruit a Natural Cancer Killer Fruit? | Soursop Health Benefits

Graviola which very much resembles a Custard Apple is a miracle fruit that is getting popular for its anti-cancer properties. Also called as Soursop, Graviola has many medicinal uses. Let’s see the many Graviola health benefits and check Graviola treatment for cancer.

Is Graviola Fruit a Natural Cancer Killer Fruit? | Soursop Health Benefits

Graviola which very much resembles a Custard Apple is a miracle fruit that is getting popular for its anti-cancer properties. Also called as Soursop, Graviola has many medicinal uses. Let’s see the many Graviola health benefits and check Graviola treatment for cancer. A humble fruit, Graviola or soursop mainly found in the rain forests of […]

Top 8 Anti Cancer Foods You Must Include in Diet to Protect Against Cancer

Cancer can be avoided by boosting the body's immune system by regular consumption of several healthy foods, herbs, fruits and vegetables. In this post, we will talk about the anti cancer foods.

Top 8 Anti Cancer Foods You Must Include in Diet to Protect Against Cancer

Garlic, an Important Anti Cancer Food Researches in the past demonstrated that garlic can play a huge role in decreasing the development of cancer cells. Garlic has also been shown as an excellent anti cancer food which can be effective in preventing colon, stomach and esophageal cancers. An active chemical known as allyl sulfur present […]

APAC Biotech’s Immuno-oncology drug Apceden gets approved in India

The Indian FDA (CDSCO - Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, ovarian, colo-rectal and non small cell lung carcinoma form of cancers.

APAC Biotech’s Immuno-oncology drug Apceden gets approved in India

The Indian FDA (CDSCO – Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, ovarian, colo-rectal and non small cell lung carcinoma form of cancers. Following a stringent review of the application submitted by the Indian biotechnology company, the Indian […]

Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

Check out details of Astrazeneca Ovarian Cancer Drug, Lynparza which in a phase 3 trial has been demonstrated to have improved survival of patients treated with Lynparza Ovarian Cancer Tablets.

Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with germline BRCA-mutations (gBRCA) who had a relapse of the disease, who did not respond to platinum-based chemo. Phase 3 Trial of Astrazeneca Ovarian Cancer Drug Lynparza The observation of the […]

Roche breast cancer drug combo cuts death rate and recurrence

Roche breast cancer drug, Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy has been demonstrated in a phase 3 trial to have cut the risk of disease recurrence besides increasing the life span of patients with an aggressive form of early breast cancer.

Roche breast cancer drug combo cuts death rate and recurrence

Roche breast cancer drug, Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy has been demonstrated in a phase 3 trial to have cut the risk of disease recurrence besides increasing the life span of patients with an aggressive form of early breast cancer. Roche Breast Cancer Trial APHINITY Results The breast cancer drug combination which met […]

Lung cancer drug Oncoprex phase II trial : Genprex reports positive interim data results

Lung cancer drug Oncoprex phase II trial : Genprex reports positive interim data results

Texas based bio-pharma Genprex has announced positive interim data from an ongoing phase II clinical trial of its lung cancer drug candidate Oncoprex. Titled as NCT01455389, the phase II trial of Oncoprex is evaluating the investigational immunogene therapy drug candidate in combination with erlotinib (Tarceva), a tyrosine kinase inhibitor (TKI) in patients with late stage […]